| CAS NO: | 55986-43-1 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 55986-43-1 |
| 别名 | 西他苯 |
| 化学名 | 4-(hexadecylamino)-benzoic acid |
| Canonical SMILES | CCCCCCCCCCCCCCCCNC1=CC=C(C(O)=O)C=C1 |
| 分子式 | C23H39NO2 |
| 分子量 | 361.6 |
| 溶解度 | ≤1mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Cetaben is an unique PPARα-independent peroxisome proliferator. The fibrate class of hypolipidemic drugs, such as fenofibrate and clofibrate, elicit their effects via binding to and activating peroxisome proliferator-activated receptor α (PPARα). In vitro: Previous study showed that cetaben could cause little but reversible proliferation and morphological heterogeneity with the occurrence of dumbbell- and cup-shaped peroxisomal profiles. Peroxisomes in HepG2 cells showed marked variation in size and shape. Cetaben treatment of HepG2 cells was able to lead to disintegration of Golgi regions and augmented mitochondrial matrix [1]. In vivo: Animal study found that the changes in large scale of liver non-peroxisomal parameters were compared after 10 days administration of both cetaben and clofibric acid 200 mg/kg/day to male Wistar rats. No analogical changes were observed after cetaben treatment in the livers of experimental animals. It was also found that both drugs could increase the activities of alanine-glyoxylate aminotransferase-1 and acetylcarnitine transferase--enzymes with proven mitochondrial and peroxisomal location. Contrary to clofibric acid, cetaben did not increase solubilization of peroxisomal enzymes [2]. Clinical trial: So far, no clinical study has been conducted. References: |
m.cnreagent.com